Recruiting IgA Nephropathy Studies in Phoenix
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
The primary objective of this study to evaluate efficacy of ravulizumab compared with placebo on proteinuria reduction and change in eGFR in adult participants with IgAN who are at risk of disease pro...
Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)
The purpose of this study is to evaluate the efficacy of povetacicept in adult participants compared with placebo in reducing proteinuria and preserving renal function....
About IgA Nephropathy Clinical Trials in Phoenix
IgA nephropathy is the most common form of glomerulonephritis worldwide, caused by deposits of immunoglobulin A in the kidneys. It can lead to kidney inflammation and progressive kidney damage. Treatment includes blood pressure management, immunosuppression, and newer targeted therapies.
There are currently 2 iga nephropathy clinical trials recruiting participants in Phoenix, ARIZONA. These studies are seeking a combined 990 participants. Research is being sponsored by Alexion Pharmaceuticals, Inc., Alpine Immune Sciences Inc, A Subsidiary of Vertex. Clinical trial participation is free and participants receive study-related medical care at no cost.
IgA Nephropathy Clinical Trials in Phoenix — FAQ
Are there iga nephropathy clinical trials in Phoenix?
Yes, there are 2 iga nephropathy clinical trials currently recruiting in Phoenix, ARIZONA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Phoenix?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Phoenix research site will contact you about next steps.
Are clinical trials in Phoenix free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Phoenix studies also compensate for your time and travel.
What iga nephropathy treatments are being tested?
The 2 active trials in Phoenix are testing new therapies including novel drugs, biologics, and treatment approaches for iga nephropathy.
Data updated March 2, 2026 from ClinicalTrials.gov